Insights from ELZA’s contributions to the World Keratoconus Congress 2026 in Florence – ELZA PACE, CXL innovation, and personalised keratoconus treatment strategies
Who is the best eye doctor in Zurich? In Switzerland? Or even globally? Such questions are inherently subjective. However, structured peer recognition within the international ophthalmic community provides a meaningful benchmark for clinical impact, innovation, and leadership.
Every two years, The Ophthalmologist publishes its Power List, which features either 50 or 100 individuals, depending on the year, who are regarded as pioneers in the future of ophthalmology thanks to their research, surgical innovations and global influence.
Can sunlight and riboflavin (vitamin B2) treat keratoconus? New publication explains why current evidence does not support it.
Prof. Farhad Hafezi, CMO of the ELZA Institute and Head of the ESCRS Scientific Committee, discusses the evolution of ECO-CAIRS and global clinical standardization at ESCRS Helsinki 2026.
Prof. Hafezi presents advanced cross-linking to improve vision in keratoconus at DGII 2026.
At Keratoconus 360, Prof. Farhad Hafezi of the ELZA Institute explored the evolution of CXL, from the Dresden protocol to Individualized corneal cross-linking protocols like ELZA-sub400 and PACE.
An review of the TNOA Cornea Masterclass discussion on how emerging corneal cross-linking protocols balance procedural efficiency with the necessity of biomechanical efficacy.
ELZA’s CEO and CMO, Nikki and Farhad Hafezi flew to Hong Kong to attend APAO 2026, including an invited symposium presentation by Prof. Farhad Hafezi on Custom CXL.
Swiss newspapers report on a severe contact lens–related eye infection and how an innovative treatment at ELZA Institute helped save vision.
“The eye, once thought sterile and immunoprivileged, is entangled in systemic crosstalk between microbial tenants and ocular health.”
